Latest news with #Novonesis
Business Wire
a day ago
- Business
- Business Wire
Bruker Launches Revolutionary timsOmni TM Mass Spectrometer
BALTIMORE--(BUSINESS WIRE)--For the 73 rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) announced the launch of the timsOmni™ system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering deep structural insights into the functional or pathological proteoforms or oligonucleotides. Multimodal eXd trapping with precise electron energy control, ion accumulation, and reaction time regulation is a cornerstone innovation of the timsOmni™ platform. This also enables CIU, further expanding the value of proteoform CCS information, followed by multiple electron-based (ECD, EID) and collision-based (CID) fragmentation techniques. The timsOmni uniquely enables protein researchers and biologics developers to tailor information-rich dissociation pathways for deeper insights - with high speed and high sensitivity. The 'Swiss-army knife' type flexibility of the timsOmni top-down capability enables the identification of low-abundant, aberrant proteoforms, the structurally altered versions of proteins arising from genetic mutations, alternative splicing, or post-translational modifications that deviate from normal physiological forms, disrupting protein function, misfolding, or aggregation, and often play critical roles in the onset and progression of human diseases, including cancer, neurodegeneration, cardiovascular disorders, and autoimmune conditions. Anders Giessing, PhD, Science Manager at Novonesis in Denmark, said, 'We use intact protein mass analysis to ensure performance, stability, and consistency of our diverse protein product portfolio. Introduction of the timsOmni, with its Swiss Army knife versatility, redefines intact mass and top-down analysis with the precision, speed, and confidence needed to provide definitive analytical support in the development and production of industrial enzymes.' The Omnitrap's signature high-sensitivity, high-speed, multimodal eXd capability is particularly powerful for mapping PTMs, such as histone proteoforms (H3:1K14ac) that play a crucial role in regulating gene expression by altering chromatin structure and controlling access to the DNA. Other PTMs like glycosylation critically influence protein folding, stability, transport, and cell signaling interactions, and detailed top-down or middle-down sequencing of complementarity-determining regions (CDRs) in humoral and therapeutic antibodies are important in cancer, autoimmunity and biologics development. Prof. Albert Heck, Professor of Chemistry and Pharmaceutical Sciences at Utrecht University and Scientific Director of the Netherlands Proteomics Center, commented, 'Proteomics will finally go 'protein-centric' by using the timsOmni. The multimodal eXd capability allows for comprehensive ion sequence ladders that are ideal for de novo sequencing and human plasma antibody repertoire profiling. Analyzing and monitoring circulating antibody levels is critical for characterizing the progression of a disease, identifying patients with delayed symptom onset, and predicting potential long-term immunity.' Frank H. Laukien, Ph.D., the CEO of Bruker Corporation, added, 'The timsOmni is a new lamppost for functional protein science, shining a light on functional and pathological proteoforms and truly enabling a new protein science paradigm for fundamental cell and molecular biology, signal transduction, cancer, neurodegeneration, and other disease research. The timsOmni will also be extremely valuable for biopharma drug discovery and development, as well as for biologics QC analysis, from therapeutic antibodies to antibody-drug conjugates.' The timsOmni is supported by OmniScape™, Bruker's next-generation top-down proteomics software that features state-of-the-art algorithms for de-isotoping complex spectra, automated charge state assignment, de novo protein sequencing support, and sequence confirmation. These key features provide unrivaled benefits for the accurate identification of proteoforms, post-translational modifications, and non-canonical proteins. OmniScape transforms complex eXd fragmentation spectra into actionable biological insights—empowering researchers to navigate the new world of functional proteoformics. Prof. Ole N. Jensen, Group Leader at the Protein Research Group of the University of Southern Denmark, observed, 'The timsOmni technology and OmniScape software already impacted our strategies for intact protein and proteoform analysis. Multimodal MS/MS fragmentation and MS3 afford very high amino acid sequence coverage and accurate localization of post-translational modifications in histones.' The timsOmni comes with the new NEOS off-line nanoESI for the extremely low infusion flow rates required for the study of protein complexes, allowing for extended analysis of scarce samples. The NEOS source works with coated and non-coated emitters. Additionally, the timsOmni retains the high sensitivity of the timsTOF Ultra 2 for nLC dia-PASEF high-throughput bottom-up 4D-proteomics. The timsOmni ushers in a new era of functional proteomics, setting the stage for landmark discoveries in ' Proteoformics ', and advancing a transformative new paradigm in protein research as it illuminates protein function through the deep sequencing of proteoforms, humoral and multi-specific antibodies, and other complex biomolecules. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit
Korea Herald
23-05-2025
- Business
- Korea Herald
Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future
SINGAPORE, May 13, 2025 /PRNewswire/ -- Novonesis, a world-leading biosolutions company, co-hosted its "Unlocking Value for a Sustainable Future" Partnering Day 2025 in Singapore on May 7 together with Novo Holdings and Flagship Pioneering. The event focused on reshaping the agriculture and food industries through biosolutions and resource recycling. Leaders from food, agri-business, and waste management explored resource optimisation, while industry executives exchanged insights into scaling innovative biosolutions. Investors identified high-growth opportunities in biosolutions and circular economy models for sustainable business impact. With the global population projected to reach 9.8 billion by 2050, pressure on food systems and sustainability is growing. Biosolutions offer a path forward using microbes, enzymes, and other technologies. The Partnering Day 2025 provided a platform for leaders in business, capital, and innovation to advance circular, bio-based solutions. Showcasing real-world advances including waste valorisation and resource optimisation, the event highlighted how biosolutions are shaping the future of food and agriculture. The event opened with a welcome address by Rasmus Bjørnø, Deputy Head of Mission at the Royal Danish Embassy in Singapore, followed by a keynote speech from Anders Spohr, Managing Partner and Head of Planetary Health at Novo Holdings, outlining the strategic role of biosolutions in reshaping agriculture and food systems. Representatives from three hosting companies shared their insights on what roles that biosolutions and capital play along the way to foster a more sustainable future. Lensey Chen, APAC President of Novonesis, Ignacio Martinez, General Partner of Flagship Pioneering, together with esteemed speakers from industry, NGOs as well as academia explored topics such as resource efficiency, the bioeconomy, and the importance of partnerships in accelerating the bio-revolution. Case studies highlighted how companies are using biosolutions to unlock new value streams and drive sustainable growth. With the planet's resources under growing strain, biosolutions are enabling transformation not just in fields and factories, but across entire value chains. In fields, factories, and homes, they are transforming production by unlocking sustainable protein sources and helping farmers increase efficiency while reducing the use of chemicals, fossil resources, energy, and water. Biosolutions also turn waste into high-value products, enabling economic growth in a sustainable way. Copenhagen Economics Report found that if we made more use of just some biosolutions, we could cut global greenhouse gas emissions by up to 4.3 billion tonnes. That's 8% of total global emissions. For every job created in biotech in general, additional 2 jobs are created across the value chain. Lensey Chen, APAC President of Novonesis, commented: "We know every customer's needs are unique, our portfolio of biosolutions is the market's broadest, and can be used to expand operations through greater flexibility. This is why partnership is key, I am happy to extend an invitation on behalf of Novonesis as a potential partner, we are here to help take our collaboration to a new level of performance by working together with you." Deepa Hingorani, Partner and Head of Planetary Health Asia, Novo Holdings added: "The bioeconomy holds exponential potential, and we see partnerships as essential to unlocking it. We hope today marks the beginning of deeper cross-sector collaboration and a shared commitment to shaping a more sustainable future together." Headquartered in Copenhagen, Novonesis was established in 2024 through the merger of Novozymes and Chr. Hansen—two pioneers in Danish biotechnology. With a portfolio spanning enzymes, microbes, and fermentation-based technologies, the company plays a pivotal role in advancing biosolutions across food, health, agriculture, and sustainability. Partnering Day 2025 reflects Novonesis' ongoing commitment to driving greater impact through innovation, collaboration, and science-based solutions. About Novonesis Novonesis is a global company leading the era of biosolutions. By leveraging the power of microbiology with science, we transform the way the world produces, consumes, and lives. In more than 30 industries, our biosolutions are already creating value for millions of consumers and benefitting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology. Learn more at About Novo Holdings Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health, and Principal Investments teams, Novo Holdings invests in life sciences companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of EUR 142 billion.
Yahoo
14-05-2025
- Business
- Yahoo
Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future
SINGAPORE, May 13, 2025 /PRNewswire/ -- Novonesis, a world-leading biosolutions company, co-hosted its "Unlocking Value for a Sustainable Future" Partnering Day 2025 in Singapore on May 7 together with Novo Holdings and Flagship Pioneering. The event focused on reshaping the agriculture and food industries through biosolutions and resource recycling. Leaders from food, agri-business, and waste management explored resource optimisation, while industry executives exchanged insights into scaling innovative biosolutions. Investors identified high-growth opportunities in biosolutions and circular economy models for sustainable business impact. With the global population projected to reach 9.8 billion by 2050, pressure on food systems and sustainability is growing. Biosolutions offer a path forward using microbes, enzymes, and other technologies. The Partnering Day 2025 provided a platform for leaders in business, capital, and innovation to advance circular, bio-based solutions. Showcasing real-world advances including waste valorisation and resource optimisation, the event highlighted how biosolutions are shaping the future of food and agriculture. The event opened with a welcome address by Rasmus Bjørnø, Deputy Head of Mission at the Royal Danish Embassy in Singapore, followed by a keynote speech from Anders Spohr, Managing Partner and Head of Planetary Health at Novo Holdings, outlining the strategic role of biosolutions in reshaping agriculture and food systems. Representatives from three hosting companies shared their insights on what roles that biosolutions and capital play along the way to foster a more sustainable future. Lensey Chen, APAC President of Novonesis, Ignacio Martinez, General Partner of Flagship Pioneering, together with esteemed speakers from industry, NGOs as well as academia explored topics such as resource efficiency, the bioeconomy, and the importance of partnerships in accelerating the bio-revolution. Case studies highlighted how companies are using biosolutions to unlock new value streams and drive sustainable growth. With the planet's resources under growing strain, biosolutions are enabling transformation not just in fields and factories, but across entire value chains. In fields, factories, and homes, they are transforming production by unlocking sustainable protein sources and helping farmers increase efficiency while reducing the use of chemicals, fossil resources, energy, and water. Biosolutions also turn waste into high-value products, enabling economic growth in a sustainable way. Copenhagen Economics Report found that if we made more use of just some biosolutions, we could cut global greenhouse gas emissions by up to 4.3 billion tonnes. That's 8% of total global emissions. For every job created in biotech in general, additional 2 jobs are created across the value chain. Lensey Chen, APAC President of Novonesis, commented: "We know every customer's needs are unique, our portfolio of biosolutions is the market's broadest, and can be used to expand operations through greater flexibility. This is why partnership is key, I am happy to extend an invitation on behalf of Novonesis as a potential partner, we are here to help take our collaboration to a new level of performance by working together with you." Deepa Hingorani, Partner and Head of Planetary Health Asia, Novo Holdings added: "The bioeconomy holds exponential potential, and we see partnerships as essential to unlocking it. We hope today marks the beginning of deeper cross-sector collaboration and a shared commitment to shaping a more sustainable future together." Headquartered in Copenhagen, Novonesis was established in 2024 through the merger of Novozymes and Chr. Hansen—two pioneers in Danish biotechnology. With a portfolio spanning enzymes, microbes, and fermentation-based technologies, the company plays a pivotal role in advancing biosolutions across food, health, agriculture, and sustainability. Partnering Day 2025 reflects Novonesis' ongoing commitment to driving greater impact through innovation, collaboration, and science-based solutions. About Novonesis Novonesis is a global company leading the era of biosolutions. By leveraging the power of microbiology with science, we transform the way the world produces, consumes, and lives. In more than 30 industries, our biosolutions are already creating value for millions of consumers and benefitting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology. Learn more at About Novo Holdings Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health, and Principal Investments teams, Novo Holdings invests in life sciences companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of EUR 142 billion. View original content to download multimedia: SOURCE Novonesis Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
08-05-2025
- Business
- Bloomberg
Trump Expected to Unveil US-UK Trade Pact & Rescind Global Chip Curbs
US President Donald Trump is expected to announce a trade agreement with the UK on Thursday, according to people familiar with the matter, in a limited deal that may nonetheless signal the direction of the US president's global trade war. Trump teased the announcement in a social media post on Wednesday night, saying he would hold an Oval Office news conference to discuss 'a MAJOR TRADE DEAL WITH REPRESENTATIVES OF A BIG, AND HIGHLY RESPECTED, COUNTRY.' Meanwhile the Trump administration plans to rescind some Biden-era AI chip curbs as part of a broader effort to revise global semiconductor trade restrictions that have drawn strong opposition from major tech companies and foreign governments. Today's guests: Kokou Agbo-Bloua, SGCIB Global Head of Economics, Cross-Asset and Quant Research, Ester Baiget, Novonesis President & CEO, Jumana Saleheen, Vanguard Chief European Economist and Investment Strategy Group Europe Head. (Source: Bloomberg)
Reuters
11-02-2025
- Business
- Reuters
Novonesis to buy DSM-Firmenich's stake in enzymes venture for $1.6 bln
COPENHAGEN, Feb 11 (Reuters) - Denmark's Novonesis ( opens new tab said on Tuesday that it had agreed to buy the stake of its partner, Swiss-Dutch chemical manufacturer DSM-Firmenich, in their joint enzymes venture for 1.5 billion euros ($1.55 billion). Get the latest news and expert analysis about the state of the global economy with the Reuters Econ World newsletter. Sign up here. Reporting by Stine Jacobsen, editing by Terje Solsvik
